Appointment of Independent Director, Internal Auditor, Secretarial Auditor, Cost Auditor and to take note of Completion of Tenure of Independent Directors
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Godavari Drugs' board, at its May 29, 2025 meeting, approved audited financial results for Q4 and FY ended March 31, 2025 with an unmodified auditor opinion from M/s Ayyadevara & Co. FY25 revenue from operations stood at Rs 11,335.01 lakhs (down from Rs 15,671.19 lakhs in FY24), with net profit of Rs 438 lakhs versus Rs 554.90 lakhs and EPS of Rs 5.82 (vs Rs 7.37). Two independent directors, Mr. Syed Anis Hussain and Mrs. Vimala Behram Madon, will retire at end of business hours on June 23, 2025 after completing two consecutive 5-year terms. Mrs. Shilpa Bung was appointed as a new independent director for a 5-year term. The board also appointed M/s S.K. Lahoti Associates as internal auditor, M/s VSS & Associates as secretarial auditor for five years, and M/s Bharathula & Associates as cost auditor for FY26. The 37th AGM is set for August 28, 2025 via video conferencing.
Shareholders should note the decline in FY25 revenue and profitability, but the clean audit report and orderly board refresh are neutral governance signals. The simultaneous exit of two long-serving independent directors and appointment of replacements may be viewed as routine succession rather than a red flag.